<DOC>
	<DOCNO>NCT01937442</DOCNO>
	<brief_summary>Objective study characterize steady-state pharmacokinetics ( PK ) thalidomide give orally monotherapy subject multiple myeloma .</brief_summary>
	<brief_title>Pharmacokinetic Study Thalidomide Subjects With Multiple Myeloma</brief_title>
	<detailed_description>This open-label , PK study multiple myeloma subject currently receive thalidomide-containing therapy newly diagnose . The study consist screen phase , baseline phase , PK phase 5-day period thalidomide treatment ( 200 mg/day ) , end-of-study evaluation Day 6 . Subjects frequent blood sample draw PK assessment Days 5 6 inpatient setting .</detailed_description>
	<mesh_term>Multiple Myeloma</mesh_term>
	<mesh_term>Neoplasms , Plasma Cell</mesh_term>
	<mesh_term>Thalidomide</mesh_term>
	<criteria>Males female â‰¥ 18 time signing informed consent document . Documented diagnosis multiple myeloma receive thalidomide contain therapy initiate thalidomidecontaining therapy . Subjects must agree temporally discontinue antimyeloma therapy study drug ( thalidomide ) least 7 day prior PK phase ( Day 1 ) post study procedure Day 6 . All Females Child Bearing Potential ( FCBP ) male subject must counsel pregnancy precaution risk fetal exposure . Females childbearing potential ( FCBP ) must : 1 . Have two negative pregnancy test verify study doctor prior start study therapy . She must agree ongoing pregnancy test course study , end study therapy . This apply even subject practice true abstinence heterosexual contact . 2 . Either commit true abstinence heterosexual contact ( must review monthly basis ) agree use , able comply , effective contraception without interruption , 28 day prior start study drug , study therapy ( include dose interruption ) , 28 day discontinuation study therapy . All female must either hysterectomy bilateral oophorectomy least 6 month screen ( proper documentation require ) OR naturally postmenopausal least 24 consecutive month ( i.e . menses time precede 24 consecutive month ) . For study , subject postmenopausal , estradiol level must &lt; 30 pg/mL plasma FSH must &gt; 40 IU/L screening . Males ( include vasectomy ) : 1 . Must practice true abstinence agree use condom sexual contact pregnant female female childbearing potential participating study , dose interruption least 28 day follow study drug discontinuation , even undergone successful vasectomy . 2 . Must agree donate semen sperm study drug therapy 4 week end study drug therapy . All subject must also counsel share thalidomide donate blood within 4 week discontinue thalidomide therapy Any significant medical condition , laboratory abnormality , psychiatric illness would prevent subject participate study ( accord Thalidomide product/prescribing information ) . Any condition include presence laboratory abnormality , place subject unacceptable risk he/she participate study ( accord Thalidomide product information ) . Any condition confound ability interpret data study ( include condition may affect absorption thalidomide , gastric bypass surgery , colon resection , etc. ) . Pregnant lactating female . Any surgical medical condition might significantly alter absorption study drug , gastrectomy , gastroenterostomy , bowel resection , pancreatic injury , pancreatitis . ( Cholecystecomy appendectomy permissible . ) Use antimyeloma agent ( thalidomide ) investigational agent within 7 day start PK phase . Prior history allergic reaction thalidomide , thalidomide excipients ( reference IB ) , relate drug ( ie , lenalidomide ) . Prior history malignancy , multiple myeloma , unless subject free disease &gt; = 3 year ( time sign ICD ) . Exceptions include follow : 1 . Basal cell carcinoma skin 2 . Squamous cell carcinoma skin 3 . Carcinoma situ cervix 4 . Carcinoma situ breast 5 . Incidental histological finding prostate cancer ( TNM stage T1a T1b ) Known human immunodeficiency virus ( HIV ) infectious hepatitis ( type A , B , C ) positivity .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>May 2016</verification_date>
	<keyword>Multiple myeloma</keyword>
	<keyword>Pharmacokinetics</keyword>
	<keyword>Thalidomide</keyword>
</DOC>